Search

Your search keyword '"Weinkove, Robert"' showing total 10 results
Start Over Author "Weinkove, Robert" Publisher american society of hematology
10 results on '"Weinkove, Robert"'

1. Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies

Author

Carrillo De Albornoz, Sara, primary, Higgins, Alisa M, additional, Petrie, Dennis, additional, Irving, Adam, additional, Fanning, Laura, additional, Weinkove, Robert, additional, Crispin, Philip, additional, Dendle, Claire, additional, Gilbertson, Michael, additional, Johnston, Anna M., additional, Keegan, Anastazia, additional, Pepperell, Dominic, additional, Pullon, Humphrey W, additional, Reynolds, John, additional, van Tonder, Tina, additional, Trotman, Judith, additional, Waters, Neil, additional, Wellard, Cameron, additional, Weston, Helen, additional, Morrissey, Orla, additional, Wood, Erica M, additional, and McQuilten, Zoe, additional

Published
2024
Full Text
View/download PDF

3. Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Author

Brown, Jennifer R., primary, Eichhorst, Barbara, additional, Hillmen, Peter, additional, Lamanna, Nicole, additional, O'Brien, Susan M., additional, Tam, Constantine S., additional, Qiu, Lugui, additional, Kaźmierczak, Maciej, additional, Jurczak, Wojciech, additional, Zhou, Keshu, additional, Šimkovič, Martin, additional, Mayer, Jiri, additional, Gillespie-Twardy, Amanda L., additional, Ferrajoli, Alessandra, additional, Ganly, Peter S., additional, Weinkove, Robert, additional, Grosicki, Sebastian, additional, Mital, Andrzej, additional, Robak, Tadeusz, additional, Österborg, Anders, additional, Yimer, Habte A., additional, Salmi, Tommi, additional, Wang, Megan (Der Yu), additional, Fu, Lina, additional, Li, Jessica, additional, Wu, Kenneth, additional, Cohen, Aileen, additional, and Shadman, Mazyar, additional

Published
2022
Full Text
View/download PDF

4. Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Author

Yeung, David T, primary, Shanmuganathan, Naranie, additional, Grigg, Andrew, additional, Cunningham, Ilona, additional, Shortt, Jake, additional, Rowling, Philip, additional, Reynolds, John, additional, Harrup, Rosemary Anne, additional, Ross, David M, additional, Kipp, David, additional, Mills, Anthony K, additional, Arthur, Christopher K, additional, Schwarer, Anthony P, additional, Jackson, Kathryn, additional, Viiala, Nicholas, additional, Weinkove, Robert, additional, Yong, Agnes S. M., additional, White, Deborah L., additional, Branford, Susan, additional, Hughes, Timothy P., additional, and ALLG, On Behalf of the, additional

Published
2019
Full Text
View/download PDF

5. Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Author

Yeung, David T, primary, Grigg, Andrew P., additional, Shanmuganathan, Naranie, additional, Cunningham, Ilona, additional, Shortt, Jake, additional, Rowling, Philip, additional, Reynolds, John, additional, Cushion, Rachel, additional, Harrup, Rosemary Anne, additional, Ross, David M, additional, Kipp, David, additional, Mills, Anthony K, additional, Arthur, Christopher K, additional, Schwarer, Anthony P, additional, Jackson, Kathryn, additional, Viiala, Nicholas, additional, Weinkove, Robert, additional, Yong, Agnes S. M., additional, White, Deborah L, additional, Branford, Susan, additional, Hughes, Timothy P., additional, and ALLG, On Behalf of the, additional

Published
2018
Full Text
View/download PDF

6. Venetoclax and obinutuzumab in chronic lymphocytic leukemia

Author

Fischer, Kirsten, primary, Al-Sawaf, Othman, additional, Fink, Anna-Maria, additional, Dixon, Mark, additional, Bahlo, Jasmin, additional, Warburton, Simon, additional, Kipps, Thomas J., additional, Weinkove, Robert, additional, Robinson, Sue, additional, Seiler, Till, additional, Opat, Stephen, additional, Owen, Carolyn, additional, López, Javier, additional, Humphrey, Kathryn, additional, Humerickhouse, Rod, additional, Tausch, Eugen, additional, Frenzel, Lukas, additional, Eichhorst, Barbara, additional, Wendtner, Clemens-M., additional, Stilgenbauer, Stephan, additional, Langerak, Anton W., additional, van Dongen, Jacque J. M., additional, Böttcher, Sebastian, additional, Ritgen, Matthias, additional, Goede, Valentin, additional, Mobasher, Mehrdad, additional, and Hallek, Michael, additional

Published
2017
Full Text
View/download PDF

7. Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)

Author

Fischer, Kirsten, primary, Al-Sawaf, Othman, additional, Fink, Anna-Maria, additional, Dixon, Mark, additional, Bahlo, Jasmin, additional, Warburton, Simon, additional, Kipps, Thomas J., additional, Weinkove, Robert, additional, Robinson, Sue, additional, Dreyling, Martin H., additional, Opat, Stephen, additional, Owen, Carolyn J., additional, López, Javier, additional, Humphrey, Kathryn, additional, Humerickhouse, Rod A., additional, Tausch, Eugen, additional, Eichhorst, Barbara, additional, Wendtner, Clemens-M., additional, Langerak, Anton W., additional, van Dongen, Jacques J.M., additional, Ritgen, Matthias, additional, Boettcher, Sebastian, additional, Stilgenbauer, Stephan, additional, Goede, Valentin, additional, Mobasher, Mehrdad, additional, and Hallek, Michael, additional

Published
2016
Full Text
View/download PDF

8. Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions

Author

Fischer, Kirsten, primary, Fink, Anna-Maria, additional, Bishop, Helen, additional, Dixon, Mark, additional, Bahlo, Jasmin, additional, Choi, Michael Y., additional, Weinkove, Robert, additional, Robinson, K. Sue, additional, Dreyling, Martin, additional, Seiler, Till, additional, Opat, Stephen, additional, Owen, Carolyn, additional, Lopez, Javier, additional, Kutsch, Nadine, additional, Tausch, Eugen, additional, Ritgen, Matthias, additional, Humerickhouse, Rod A., additional, Humphrey, Kathryn, additional, Wenger, Michael K., additional, Goede, Valentin, additional, Eichhorst, Barbara, additional, Wendtner, Clemens-Martin, additional, Stilgenbauer, Stephan, additional, Kipps, Thomas J., additional, and Hallek, Michael, additional

Published
2015
Full Text
View/download PDF

10. Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy.

Author

McQuilten ZK, Weinkove R, Thao LTP, Crispin P, Degelia A, Dendle C, Gilbertson M, Johnston A, Keegan A, Pepperell D, Pullon H, Reynolds J, van Tonder T, Trotman J, Waters N, Wellard C, Weston H, Morrissey CO, and Wood EM

Subjects
Humans, Anti-Bacterial Agents adverse effects, Doxycycline, Immunoglobulins, Feasibility Studies, Agammaglobulinemia complications, Agammaglobulinemia drug therapy, Hematologic Neoplasms complications, Hematologic Neoplasms drug therapy
Abstract

Abstract: Immunoglobulin replacement and prophylactic antibiotics are commonly used to prevent infections in patients with secondary hypogammaglobulinemia due to hematological malignancies but have never been directly compared. In this randomized controlled feasibility trial conducted in 7 hospitals in Australia and New Zealand, we enrolled patients with secondary hypogammaglobulinemia with either a history of recurrent/severe infection or an immunoglobulin G level <4 g/L. Participants were randomized in a 1:2 ratio to immunoglobulin (0.4 g/kg per 4 weeks IV) or daily antibiotics (trimethoprim-sulfamethoxazole 160 mg/800 mg or, if contraindicated, 100 mg doxycycline) for 12 months. Participants allocated to antibiotics were allowed to crossover after grade ≥3 infections. The primary outcome was proportion of patients alive on the assigned treatment 12 months after randomization. Between August 2017 and April 2019, 63 patients were randomized: 42 to antibiotics and 21 to immunoglobulin. Proportion of participants alive on allocated treatment at 12 months was 76% in the immunoglobulin and 71% in the antibiotic arm (Fisher exact test P=.77; odds ratio, 0.78; 95% CI, 0.22-2.52). The lower quartile for time to first major infection (median, not reached) was 11.1 months for the immunoglobulin and 9.7 months for the antibiotic arm (log-rank test, P=.65). Three participants in the immunoglobulin and 2 in the antibiotic arm had grade ≥3 treatment-related adverse events. A similar proportion of participants remained on antibiotic prophylaxis at 12 months to those on immunoglobulin, with similar rates of major infections. Our findings support the feasibility of progressing to a phase 3 trial. Trial registration #ACTRN12616001723471., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results